/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Silvia Mangiacavalli

Policlinico San Matteo Fondazione(IT)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

175

Papers

3.4K

Citations

26

h-index

46

i10-index

Silvia Mangiacavalli is an academic researcher from Policlinico San Matteo Fondazione. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 26, co-authored 149 publications.

ORCID: 0000-0001-9787-3083

Research Topics

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Peptidase Inhibition and Analysis Cancer Treatment and Pharmacology Chronic Lymphocytic Leukemia Research

Papers by this author

works

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

2023 · New England Journal of Medicine · 469 citations

https://doi.org/10.1056/nejmoa2312054

Pieter Sonneveld Meletios Α. Dimopoulos Mario Boccadoro Hang Quach

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study

2025 · Hematological Oncology · 9 citations

https://doi.org/10.1002/hon.70042

Enrica Antonia Martino Daniele Derudas Elena Rossi Paola Stefanoni

Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts

2025 · Annals of Hematology · 1 citations

https://doi.org/10.1007/s00277-025-06212-5

Mattia D’Agostino Marina Martello Lorenzo De Paoli Silvia Mangiacavalli

MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations

https://doi.org/10.1016/s2152-2650(24)01669-0

Pieter Sonneveld Philippe Moreau Meletios Α. Dimopoulos Hang Quach

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations

https://doi.org/10.1016/s2152-2650(24)00956-x

Pieter Sonneveld Philippe Moreau Meletios Α. Dimopoulos Hang Quach

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations

https://doi.org/10.1016/s2152-2650(24)00952-2

Meletios Α. Dimopoulos Pieter Sonneveld Paula Rodríguez‐Otero Hang Quach

Research topics

topics

Multiple Myeloma Research and Treatments

Protein Degradation and Inhibitors

Peptidase Inhibition and Analysis

Cancer Treatment and Pharmacology

Chronic Lymphocytic Leukemia Research

Chat about Author

Papers

Chat

Click to start Chat